Integer price target raised to $130 from $124 at Citi

Citi raised the firm’s price target on Integer to $130 from $124 and keeps a Neutral rating on the shares. The firm wonders if the recent rally in medical technology shares can hold heading into the Q3 reports. Citi enters earnings season “cautious,” saying Q3 is historically the toughest quarter in MedTech as it brings scrutiny over the 2025 setup and commentary on next year’s numbers “could be a governor of price action in the near-term.” The firm maintains its top picks on Boston Scientific (BSX), GE HealthCare (GEHC) and Insulet (PODD).